Roche’s next big breast cancer drug, Wilserdly, secures FDA approval as 4th oral SERD

Roche building
Monday's FDA approval is less important for Roche's Wilserdly compared with an upcoming regulatory decision in the adjuvant setting for breast cancer. (Photo by FABRICE COFFRINI/AFP via Getty Images)

No breast cancer asset in Roche’s pipeline carries a higher valuation than giredestrant. In fact, the Swiss drugmaker’s pharmaceuticals chief has touted the oral SERD as potentially the company’s “largest-selling product.”

On Monday, giredestrant took the first step toward what some analysts project could exceed $10 billion in peak annual sales, winning FDA approval in combination with everolimus for certain patients with HR-positive, HER2-negative breast cancer.

However, despite a nearer target action date at the end of November, the FDA approval wasn’t about the more important early-stage breast cancer setting. Instead, the agency cleared giredestrant, to be marketed as Wilserdly, for patients with previously treated ESR1-mutated advanced tumors, the same narrow indication where two other oral selective estrogen receptor degraders (SERDs) are already approved. The FDA’s decision in this niche came a month ahead of schedule.

Nevertheless, in its Nov. 16 announcement, Roche was quick to highlight that Wilserdly-everolimus is so far the only oral SERD combo to significantly outperform standard endocrine therapy in a phase 3 trial where all patients had previously tried a CDK4/6 inhibitor, which has become the standard of care in first-line treatment.

In the phase 3 evERA trial, Wilserdly-everolimus reduced the risk of progression or death by 62% compared with standard endocrine therapy plus everolimus among patients with CDK4/6-pretreated, ESR1-mutated, HR-positive, HER2-negative breast cancer. Median progression-free survival reached 10 months for the Wilserdly arm, versus 5.5 months for the comparator group.

Before Wilserdly’s arrival, the FDA had approved Menarini’s Orserdu and Eli Lilly’s Inluriyo, also in second-line ESR1-mutated tumors, a resistance mechanism that often develops in HR+/HER2- metastatic breast cancer after aromatase inhibitor therapy. 

In September, Lilly escalated the oral SERDs’ ESR1 competition through an FDA label expansion for use alongside the company’s CDK4/6 inhibitor Verzenio. In the phase 3 Ember-3 trial, Inluriyo-Verzenio led to a 47% PFS benefit versus Inluriyo alone, extending median PFS to 11.1 months, versus 5.5 months, respectively. 

Amid the second-line battle, the FDA surprised industry watchers with an approval for AstraZeneca’s Etcamah in a novel first-line-switch setting for patients who developed ESR1 mutation during initial first-line treatment with an aromatase inhibitor and a CDK4/6 drug. The go-ahead was controversial because it went against a negative advisory committee recommendation, and because the phase 3 Serena-6 trial didn’t answer whether that first-line-switch approach works at least as well as the traditional method of treating patients upon disease progression.

Meanwhile, both Etcamah and Wilserdly failed in the first-line setting, where ESR1 mutations are rare. 

Despite the first-line flop, Roche Pharmaceuticals CEO Teresa Graham still argued that Wilserdly “could be our largest-selling product.” The Swiss pharma has placed its biggest bet on adjuvant treatment of early-stage breast cancer, which, as Graham noted, sees three times more drug-treated patients than in the first-line metastatic setting, plus a much longer treatment duration. 

“It is really important to remember that the first-line metastatic breast cancer setting only represented around 10% of the overall giredestrant opportunity,” whereas the adjuvant use accounts for about 70%,” she said during an investor call in April.

In the adjuvant setting, Roche’s lidERA trial has succeeded, showing a statistically significant invasive disease-free survival benefit for Wilserdly versus standard endocrine therapy. The FDA is scheduled to rule on that potential first-in-class adjuvant use by Nov. 30. And Roche expects a single-arm sub-study to answer some critical CDK4/6 combination questions this year. 

The company has put Wilserdly’s peak sales projection at above 3 billion Swiss francs. In an October note, Jefferies’ analysts modeled risk-adjusted Wilserdly revenues of 4.8 billion Swiss francs by 2034, versus consensus of 6.6 billion Swiss francs.